Longevity News
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
Adaptyx has demonstrated the first continuous wearable measurement of free cortisol across multiple days in humans, capturing real-time hormone dynamics rather than isolated snapshots. This shift from point-in-time testing to continuous monitoring addresses a fundamental gap in understanding how cortisol rhythms — not just absolute levels — drive metabolic health, glucose regulation, and stress resilience.
South Korea has officially integrated ring-based cuffless blood pressure monitoring into hypertension treatment guidelines, marking the first regulatory recognition of this technology worldwide. Continuous, non-invasive monitoring addresses a critical gap in detecting masked and nocturnal hypertension—dangerous blood pressure elevations that standard clinic measurements miss.
Magnesium functions as a central regulator of mitochondrial ATP production and metabolic resilience, with age-related declines in cellular magnesium contributing to insulin resistance, metabolic inflexibility, and accelerated aging. This positions magnesium homeostasis as a mechanistic checkpoint linking energy production capacity to disease risk and longevity.
Surgery impairs memory and brain cell regeneration in aged mice by disrupting cholinergic signaling from the medial septum to the hippocampus. Restoring this pathway through pharmacological or sustained neural activation reverses both cognitive and neurogenic deficits, suggesting a tractable mechanism for postoperative cognitive dysfunction.
Aged skeletal muscle exhibits an exaggerated mitochondrial unfolded protein response to physical stress, driven by reduced protein-folding capacity and elevated reactive oxygen species signaling. This amplified stress response reflects compromised mitochondrial resilience and suggests potential targets for preserving muscle function during aging.
Lifelong time-restricted feeding extended healthspan in mice on standard diets, with distinct sex-specific effects on aging pathologies and lifespan. This finding suggests temporal eating patterns influence fundamental aging processes independent of caloric restriction or weight loss.
Intranasal Protollin, a pathogen-associated molecular pattern (PAMP), shifts immune activation in early Alzheimer's disease by enhancing monocyte phagocytosis while reducing CD8+ T cell cytotoxicity in a Phase 1 trial. This immune recalibration addresses a core driver of neuroinflammation implicated in cognitive decline.
Mechanical stress suppresses miR-330 expression in cartilage and bone, driving osteoarthritis progression through increased inflammation and cell death. Restoring miR-330 via gene therapy protects against load-induced cartilage and bone degeneration in animal models, suggesting a tractable target for preventing occupational and age-related joint disease.
Winona established a research initiative providing funding, mentorship, and resources to early-career clinicians and trainees conducting menopause and women's health research. The program addresses a documented funding gap: women's health research received only 8.8 percent of NIH grant spending between 2013 and 2023, with that share declining over the period.
Niagen Bioscience renamed its research program to align with company branding while expanding support for NAD+ science across 300+ collaborations and 45+ peer-reviewed human studies. The initiative now prioritizes clinical investigation into energy metabolism, cognitive function, cardiovascular health, and immune response through both oral and pharmaceutical-grade formulations.
Elevated arterial stiffness associates with a distinct CD4+ T cell immune remodeling pattern characterized by increased TCR diversity, chronic activation, and functional impairment—a process mechanistically separate from classical immunosenescence. This CD4+-driven trajectory offers a novel immune signature for identifying subclinical vascular risk before clinical disease emerges.
Cambrian Bio will present Phase 1b data on ATX-304, an oral small molecule combining AMPK activation with mitochondrial support, in prediabetic obese participants at the American Diabetes Association Scientific Sessions in June 2026. The compound targets metabolic sensing pathways that decline with age, addressing a significant driver of age-related cardiometabolic disease.